NeoGenomics Inc (NEO)
15.14
-0.44
(-2.79%)
USD |
NASDAQ |
May 08, 11:07
NeoGenomics Cash from Operations (TTM): -15.18M for March 31, 2024
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
March 31, 2024 | -15.18M |
December 31, 2023 | -1.953M |
September 30, 2023 | -23.42M |
June 30, 2023 | -34.20M |
March 31, 2023 | -49.64M |
December 31, 2022 | -65.99M |
September 30, 2022 | -82.08M |
June 30, 2022 | -73.58M |
March 31, 2022 | -57.97M |
December 31, 2021 | -26.72M |
September 30, 2021 | -0.962M |
June 30, 2021 | 7.331M |
March 31, 2021 | 10.60M |
December 31, 2020 | 1.46M |
September 30, 2020 | -1.166M |
June 30, 2020 | 16.94M |
March 31, 2020 | 10.34M |
December 31, 2019 | 23.37M |
September 30, 2019 | 35.46M |
June 30, 2019 | 25.21M |
March 31, 2019 | 36.57M |
December 31, 2018 | 44.79M |
September 30, 2018 | 35.09M |
June 30, 2018 | 34.15M |
March 31, 2018 | 34.04M |
Date | Value |
---|---|
December 31, 2017 | 18.04M |
September 30, 2017 | 12.04M |
June 30, 2017 | 14.22M |
March 31, 2017 | 12.73M |
December 31, 2016 | 21.48M |
September 30, 2016 | 23.84M |
June 30, 2016 | 16.59M |
March 31, 2016 | 14.24M |
December 31, 2015 | 6.393M |
September 30, 2015 | 5.258M |
June 30, 2015 | 6.049M |
March 31, 2015 | 7.638M |
December 31, 2014 | 9.45M |
September 30, 2014 | 7.959M |
June 30, 2014 | 6.992M |
March 31, 2014 | 4.582M |
December 31, 2013 | 2.227M |
September 30, 2013 | 2.733M |
June 30, 2013 | 0.025M |
March 31, 2013 | -0.757M |
December 31, 2012 | -0.492M |
September 30, 2012 | 0.746M |
June 30, 2012 | 1.139M |
March 31, 2012 | 0.548M |
December 31, 2011 | 0.069M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-82.08M
Minimum
Sep 2022
35.46M
Maximum
Sep 2019
-15.11M
Average
-1.560M
Median
Cash from Operations (TTM) Benchmarks
Teladoc Health Inc | 345.78M |
Abbott Laboratories | 7.143B |
Halozyme Therapeutics Inc | 388.57M |
Verastem Inc | -86.46M |
Ocugen Inc | -62.05M |